WP
CORT icon

Woodline Partners’s Corcept Therapeutics CORT Stock Holding History

Woodline Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-912,391
Closed -$18.5M – 659
2022
Q4 		$18.5M Buy
912,391
+550,417
+152% +$13.8M 0.25% 121
2022
Q3 		$9.28M Buy
+361,974
New +$9.69M 0.13% 208
2021
Q3 		– Sell
-213,080
Closed -$4.69M – 694
2021
Q2 		$4.69M Sell
213,080
-245,421
-54% -$5.46M 0.09% 230
2021
Q1 		$10.9M Sell
458,501
-107,391
-19% -$2.87M 0.24% 106
2020
Q4 		$14.8M Buy
+565,892
New +$11.9M 0.39% 80

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Woodline Partners's CORT Position: Q1 2023 in Review

Woodline Partners sold out of Corcept Therapeutics (CORT) in Q1 2023, closing a stake of 912,391 shares — an estimated $18.5M sold.

Woodline Partners first reported a position in CORT in Q4 2020 and held it in 5 quarters. The position peaked at $18.5M in Q4 2022. 232 funds tracked by Wall St. Rank hold CORT as of Q1 2023.

  • Woodline Partners reported no remaining Corcept Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Woodline Partners sold 912,391 Corcept Therapeutics shares in Q1 2023, an estimated $18.5M.
  • Woodline Partners first reported a position in Corcept Therapeutics in Q4 2020 and held it in 5 quarters.
  • Woodline Partners's Corcept Therapeutics position peaked at $18.5M in Q4 2022.
  • 232 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2023.

Based on Woodline Partners's 13F filing for Q1 2023, filed 15 May 2023.